Navigation Links
Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
Date:11/29/2007

JERUSALEM, November 29 /PRNewswire/ -- Jerusalem Global Ventures today announced that it will soon be launching JGV Growth Equity Fund, L.P., a $200 million fund. The Fund will invest in private Israeli related technology companies that are on a trajectory to IPO within three years and have a proven business model. First closing is scheduled for April 2008.

Dr. Shlomo Kalish, who founded Jerusalem Global in 1994, notes that, "Unlike the early stage VC investment model, where one expects multiple write-offs for every 'home run', this Fund's business model should produce quicker turnaround of money, lower risk, and more predictable returns." In 2007, Dr. Kalish was the only Israeli in the Top 50 of the Forbes Midas list.

Jerusalem Global currently manages two sector funds launched in 1999. When compared to peers of the same vintage, one of those funds is at the top in terms of both cash distribution and IRR. Jerusalem Global's spokesman said, "We believe the record of the second fund will be as good or better when the remaining portfolio companies are exited."

Dr. Yoseph Linde, who co-managed the prior Funds, commented, "Over the last several years, in the course of making investments for our early-stage VC fund, we were offered numerous opportunities to invest in late-stage technology companies. Although we rejected most of these offers as they did not fit our primarily early stage focus, we did make two such investments resulting in two successful exits. Our portfolio company, Mellanox, which had a successful IPO earlier this year, would be a perfect example of companies we'd fund." Dr. Linde was a successful serial entrepreneur before joining Jerusalem Global Ventures.

The Fund expects to invest $5-20 million in companies which late-stage financing needs of $10-50 million. Dr. Kalish said, "Think of this Fund as a barbell. On one end we have foreign financial institutions that do not have staff on the ground in Israel but have exp
'/>"/>

SOURCE Jerusalem Global Ventures Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...all/ -- American,HealthChoice, Inc. (Pink Sheets:...medical services company with medical clinics in T...rst sales of the U.S. FDA approved OmniBody Scan, ...atterns of abnormality within,the human body and ...d,treatment. , "Physicians purchasing thes...
(Date:11/19/2008)...-FirstCall/ -- Bavarian Nordic,has invoiced the U...SD 25,million as allowed under the RFP-3 contract...he company,s IMVAMUNE(R) smallpox vaccine. This mi...ssion of a clinical safety report,from a large Ph...ects, which,is part of the regulatory package tha...
(Date:11/19/2008)...Therapeutics Inc., a,privately-held biotechnology...,hydrolase (s-EH) inhibitors, today announced tha... financing. Frazier Healthcare Ventures and Alta,...lso included existing,investors Burrill & Com...ce,Ventures. This financing completes the Series...
(Date:11/19/2008)...ociates Architects,( http://www.kornberg.com ) ha...,retained by the Okinawa Institute for Science an...nt funded scientific research campus and graduate,...made the announcement. , "Having a presence...solidifies our international capabilities," said K...
Breaking Biology Technology:American HealthChoice Announces the First Sales of the OmniBody Scan 2Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities 2Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing 2Kornberg Associates Architects Opens Tokyo Office 2
...At least six Wisconsin biotech companies will pres...t that may be another signal of the rising influen...rums. , ,The Wisconsin companies will travel to Mi...tureForum , sponsored by the Biotechnology Indust...plans and technology developments to venture capit...
...The natural world has been medicine,s most effecti...our most potent anti- cancer drugs. , ,Now, with h...nsortium of University of Wisconsin-Madison scient...scovery by copying and improving nature,s designs ...ervical and pancreatic cancer. , ,The new effort w...
...owth consulting company has honored an MRI vital s...ith the 2005 Customer Value Enhancement Award. , ,...ems, Inc. , of Milwaukee through an OEM agreement ...itoring market area. , ,The Veris monitor was join... was launched in March and is considered by Critic...
...ildren,s Hospital and Health System in Milwaukee ...cal Manager advanced clinical information solution...cording to Eclypsis Corp, of Boca Raton, Fla. , ...ED Manager, Pharmacy Benefits Manager, Sunrise Sec..., a comprehensive clinical documentation solution....
Other Biology Technology:Six Wisconsin firms to present at BIO Mid-America VentureForum 2Six Wisconsin firms to present at BIO Mid-America VentureForum 3UW-Madison scientists to mimic nature for newest cancer drugs 2UW-Madison scientists to mimic nature for newest cancer drugs 3
(Date:11/19/2008)...gineered trachea (windpipe), utilising the patient...ted into a young woman with a failing airway. The ...ient with a normally functioning airway, thereby s...ide crucial new evidence that adult stem cells, co... offer genuine solutions to other serious illnesse...
(Date:11/19/2008)... created by a University of Central Florida profes...r tumors. , Associate Professor James Turkson,s ...st cancer tumors in tests on mice. The compounds,...protein called STAT3, and researchers have observe...nds are very promising," Turkson said. "They,ve wo...
(Date:11/19/2008)... in the scientific journal PLoS ONE highlights h... humankind. This is the story of a voyage of disco...identification of the molecules responsible and th...y marine organisms such as sea anemones and corals...iety of dazzling hues. Fluorescent proteins have r...
(Date:11/19/2008)... created by a University of Central Florida profes...r tumors. , Associate Professor James Turkson,s ...st cancer tumors in tests on mice. The compounds,...protein called STAT3, and researchers have observe...nds are very promising," Turkson said. "They,ve wo...
Breaking Biology News(10 mins):Adult stem cell breakthrough 2Adult stem cell breakthrough 32 new compounds show promise for eliminating breast cancer tumors 2Biomedical research profits from the exploration of the deep sea 2Two new compounds show promise for eliminating breast cancer tumors 2New research tools are too complex for easy answers researchers say 8852 1New research tools are too complex for easy answers researchers say 8852 2New research tools are too complex for easy answers researchers say 8852 3Copy number variation may stem from replication misstep 1735 1Copy number variation may stem from replication misstep 1735 2Copy number variation may stem from replication misstep 1735 3Research Offers Promise for Cirrhosis Treatment 8850 1Research Offers Promise for Cirrhosis Treatment 8850 2In largest U S Hep C trial researchers determine weight based dosing is key to optimal treatment 8848 1In largest U S Hep C trial researchers determine weight based dosing is key to optimal treatment 8848 2In largest U S Hep C trial researchers determine weight based dosing is key to optimal treatment 8848 3In largest U S Hep C trial researchers determine weight based dosing is key to optimal treatment 8848 4
...ea benefit significantly from longer nightly use o...vice to improve breathing during sleep, according ...ng, and Blood Institute (NHLBI) of the National In...ntify the nightly duration of CPAP use needed to g...tioning. , Researchers at seven sleep centers in ...
... candles. , These tiny tubes are constructed from ...bout 100,000 laid side-by-side to span the width o...entists have discovered that some individual nanot... are bathed in light. Some glow brightly. Others g...r. , Until now, this property has been largely a...
...roscience Institute at the University of Cincinnat...incorporate—in real time—two high-tech imaging too...nal abilities of patients who undergo brain surger... colleagues are among the first in the United Stat...g (MRI) and “diffusion tensor tractography” data t...
...ered a gene that, when mutated, causes one of the .... Scientists at the University of Leeds, working i...ound the world, identified the gene, which is esse... "see" light. , The finding, the thirteenth gene ..., comes at a time of hope for the people born with...
Other Biology News:Longer treatment benefits sleep apnea patients 2Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3Dual-imaging technique useful before -- and during -- brain surgery 2'Lucky 13' as new gene discovery offers further hope for childhood blindness 2'Lucky 13' as new gene discovery offers further hope for childhood blindness 3